Stock 688238 OBIO TECHNOLOGY (SHANGHAI) CORP., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Obio Technology (Shanghai) Corp., Ltd.

Equities

688238

CNE1000059N9

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 04/06/2024 am IST 		5-day change 1st Jan Change
5.26 CNY -2.77% Intraday chart for Obio Technology (Shanghai) Corp., Ltd. -3.31% -41.49%
30/05 OBiO Technology Officially Launches the Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases CI
16/05 Obio Technology's Shareholders to Offload Up to 1.5% Stake MT

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 9,400 5,820 3,405 - -
Enterprise Value (EV) 1 9,400 5,820 3,405 3,405 3,405
P/E ratio 230 x -45.2 x -29.2 x 297 x -
Yield - - - - -
Capitalization / Revenue 32.3 x 27.3 x 9.99 x 7.58 x 9.18 x
EV / Revenue 32.3 x 27.3 x 9.99 x 7.58 x 9.18 x
EV / EBITDA 143 x -48.7 x 75.1 x 38.4 x -
EV / FCF - -9.14 x -16 x -21.3 x 106 x
FCF Yield - -10.9% -6.25% -4.7% 0.94%
Price to Book 4.33 x 2.82 x 1.75 x 1.34 x -
Nbr of stocks (in thousands) 6,41,146 6,47,433 6,47,433 - -
Reference price 2 14.66 8.990 5.260 5.260 5.260
Announcement Date 23/02/23 23/02/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 - 291.3 213 340.9 449.2 371
EBITDA 1 - 65.77 -119.4 45.36 88.64 -
EBIT 1 - 41.71 -156.1 -123 13 -
Operating Margin - 14.32% -73.26% -36.09% 2.89% -
Earnings before Tax (EBT) 1 - 41.62 -156.2 -123 5.5 -
Net income 1 54.26 39.03 -128 -116 10.17 -
Net margin - 13.4% -60.09% -34.03% 2.26% -
EPS 2 0.1077 0.0638 -0.1990 -0.1800 0.0177 -
Free Cash Flow 1 - - -637 -213 -160 32
FCF margin - - -299.01% -62.49% -35.62% 8.63%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 02/03/22 23/02/23 23/02/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 - - -637 -213 -160 32
ROE (net income / shareholders' equity) - 2.12% -6.06% -0.58% 1.36% -
ROA (Net income/ Total Assets) - 1.75% -4.98% -4.5% -0.25% -
Assets 1 - 2,233 2,573 2,578 -4,067 -
Book Value Per Share 2 - 3.390 3.190 3.000 3.930 -
Cash Flow per Share 2 - 0.0300 -0.1400 -0.1600 0.1200 -
Capex 1 - 484 547 103 67.5 38
Capex / Sales - 166.29% 256.71% 30.22% 15.03% 10.24%
Announcement Date 02/03/22 23/02/23 23/02/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Obio Technology (Shanghai) Corp., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.26 CNY
Average target price
8.2 CNY
Spread / Average Target
+55.89%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
OBIO TECHNOLOGY (SHANGHAI) CORP., LTD. Stock Obio Technology (Shanghai) Corp., Ltd.
-41.49% 48Cr
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+42.83% 75TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
+34.11% 60TCr
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.70% 36TCr
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.06% 33TCr
ABBVIE INC. Stock AbbVie Inc.
+4.63% 28TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.02% 24TCr
NOVARTIS AG Stock Novartis AG
+9.26% 21TCr
ROCHE HOLDING AG Stock Roche Holding AG
-4.21% 21TCr
PFIZER, INC. Stock Pfizer, Inc.
+2.43% 17TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 688238 Stock
  4. Financials Obio Technology (Shanghai) Corp., Ltd.